Skip to content

The Loki zupa in the treatment of patients with abnormal phlegmatic temperament bronchial asthma: a multicenter, randomised, double-blind, placebo controlled clinical trial

The Loki zupa in the treatment of patients with abnormal phlegmatic temperament bronchial asthma: a multicenter, randomised, double-blind, placebo controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008106
Enrollment
Unknown
Registered
2016-03-16
Start date
2014-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Treatment group:Seretide +Loki zupa
Control group:Seretide +Placebo of Loki zupa

Sponsors

Huashan Hospital Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 70 years old, male or female; 2.Patients with bronchial asthma inhaled corticosteroid or received other formal routine treatment after 3 months, ACT scores < 20; 3.Patients with asthma can finish diary records of asthma at the introduction phases; 4.Patients with abnormal phlegmatic temperament type according to Uighur Medicine; 5.Without respiratory tract infection and acute asthma attack or no oral and intravenous use of glucocorticoid treatment for the past two weeks; 6.Able and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe persistent asthma or acute asthma attack or Oral glucocorticoid treatment; 2. Patients with abnormal blood tape or abnormal black bile tape or abnormal biliary fluid tape according to Uighur Medicine; 3. Previous diagnosis of COPD or other pulmonary diseases; 4. Pregnant or planning pregnancy, breast-feeding women; 5. .Patients with malignant tumor or hematological disease; 6.Participated in clinical trials of other drugs for the past three months; 7. Heart, liver and kidney function for severe damage (cardiac function grade 3 ~ 4, ALT and/or the AST 1.5 times more than normal ceiling above, Cr over the normal limit); 8. Researchers think that he or she doesn't fit into the group for other conditions.

Design outcomes

Primary

MeasureTime frame
Asthma control test;

Secondary

MeasureTime frame
Asthma symptoms, lung function, Asthma Quality of Life, Questionnaire, Uighur Medicine syndrome, blood cell count;

Countries

China

Contacts

Public ContactJingcheng Dong

Huashan Hospital Fudan University

jcdong2004@126.com+86 021 52888301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026